Acción 300558 BETTA PHARMACEUTICALS CO., LTD.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Betta Pharmaceuticals Co., Ltd.

Acciones

300558

CNE100002DD9

Precio de cierre Shenzhen S.E.
Otros sitios de cotización
 00:00:00 26/04/2024 		Varia. Cinco días. Varia. 1 de enero.
40,54 CNY +3,66 % Gráfico intradía de Betta Pharmaceuticals Co., Ltd. +12,49 % -21,36 %
19/04 Betta Pharmaceuticals Co. informa de los resultados del primer trimestre finalizado el 31 de marzo de 2024 CI
2023 Betta Pharmaceuticals Co. informa de los resultados de los nueve meses finalizados el 30 de septiembre de 2023 CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
C4 Therapeutics, Inc. announced that it has received $24.999997 million in funding from Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
Beijing Mabworks Biotech Co., Ltd. announced that it expects to receive CNY 150.000042 million in funding from Betta Pharmaceuticals Co., Ltd.
C4 Therapeutics Shares Up 18% After Lung Cancer Drug Application Receives FDA Clearance
Betta Pharmaceuticals Gets Nod for Voronib Tablets' Listing
Betta Pharmaceuticals Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 15 June 2023
C4 Therapeutics, Betta Pharmaceuticals Sign Deal to Develop, Commercialize CFT8919 in Greater China
C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC Degrader of EGFR L858R for NSCLC
C4 Therapeutics, Inc. announced that it expects to receive $24.999997 million in funding from Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co., Ltd. Approves Cash Dividend for the Year of 2022
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
Betta Pharmaceuticals Co., Ltd. Announces Profit Distribution Proposal for 2022
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
Betta Pharmaceuticals Gets Nod to Start Clinical Trial of Tumor Drug in China
Betta Pharmaceuticals Co., Ltd. cancelled the transaction announced on June 13, 2022
Betta Pharmaceuticals Co., Ltd. Approves Board Elections
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción 300558
  4. Noticias Betta Pharmaceuticals Co., Ltd.
  5. Otros idiomas